BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 05/25/21

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting Superior clinical and biomarker outcomes demonstrated with NurOwn exosomes compared to MSC exosomes in Preclinical ARDS Model PR Newswire ...

BrainStorm Cell Therapeutics Inc. (BCLI) Q1 2021 Results Conference Call April 26, 2021 08:00 AM ET Company Participants Michael Wood - IR, LifeSci Advisors Chaim Lebovits - President and CEO Dr. Stacy Lindborg - EVP and Head, Global Clinical Research Dr. Ralph Kern - President and Chief Medi...

BrainStorm Cell Therapeutics (BCLI): Q1 GAAP EPS of -$0.19 beats by $0.07.Cash and equivalents, and short-term bank deposits of $40.0M.Press Release For further details see: BrainStorm Cell Therapeutics EPS beats by $0.07

BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update - Positive Phase 2 data demonstrate the potential of NurOwn® as a treatment for progressive MS - Regulatory strategy progressing to advance NurOwn's approval in ALS - Conferenc...

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) traded at a new 52-week low today of $3.04. This new low was reached on above average trading volume as 2.3 million shares traded hands, while the average 30-day volume is approximately 978,000 shares. There is potential upside of 17.3% for...

Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) traded today at $3.06, breaking its 52-week low. This new low was reached on above average trading volume as 2.3 million shares traded hands, while the average 30-day volume is approximately 978,000 shares. Potential upside of 18....

BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update PR Newswire NEW YORK , April 19, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases,...

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

Gainers: Aptose Biosciences (APTO) +65%, Brainstorm Cell Therapeutics (BCLI) +13%, Prothena (PRTA) +12%, Armata Pharmaceuticals (ARMP) +8%, Inventiva (IVA) +8%.Losers: Benitec Biopharma (BNTC) -24%, Second Sight Medical Products (EYES) -1...

BrainStorm Cell Therapeutics (BCLI) soars 20% premarket after announcing topline data from Phase 2 trial evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis ((MS)).The study achieved the pr...